Buchumschlag

Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer

Aim: To evaluate the predictive value of the expression of the secreted protein acidic and rich in cysteine (SPARC) for nab-paclitaxel in metastatic breast cancer (MBC). Patients and Methods: Forty-four patients with progressive MBC were prospectively treated with nab-paclitaxel. Expression of SPARC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schneeweiss, Andreas (VerfasserIn) , Seitz, Julia (VerfasserIn) , Smetanay, Katharina (VerfasserIn) , Schütz, Florian (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Zorn, Markus (VerfasserIn) , Sinn, Peter (VerfasserIn) , Marmé, Frederik (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: August 4, 2014
In: Anticancer research
Year: 2014, Jahrgang: 34, Heft: 11, Pages: 6609-6615
ISSN:1791-7530
Online-Zugang:Verlag, lizenzpflichtig, Volltext: http://ar.iiarjournals.org/content/34/11/6609
Volltext
Verfasserangaben:Andreas Schneeweiss, Julia Seitz, Katharina Smetanay, Florian Schuetz, Dirk Jaeger, Andreas Bachinger, Markus Zorn, Hans-Peter Sinn and Frederik Marmé
Beschreibung
Zusammenfassung:Aim: To evaluate the predictive value of the expression of the secreted protein acidic and rich in cysteine (SPARC) for nab-paclitaxel in metastatic breast cancer (MBC). Patients and Methods: Forty-four patients with progressive MBC were prospectively treated with nab-paclitaxel. Expression of SPARC in tumor cells was assessed by an immunoreactive score, integrating staining intensity and percentage of positive tumor cells; expression in stroma based on staining intensity. SPARC serum levels were determined before 1st and 2nd cycle of nab-paclitaxel and at progression. By applying several cut-offs the association between SPARC expression or serum levels and clinical end-points was analyzed. Results: No clear association between expression of SPARC in primary or metastatic tumor tissue or in serum and any clinical end-point could be detected regardless of the various cut-offs applied. Conclusion: Efficacy of nab-paclitaxel in MBC does not seem to be associated with expression of SPARC in tumor tissues or serum.
Beschreibung:Gesehen am 01.09.2020
Beschreibung:Online Resource
ISSN:1791-7530

Ähnliche Einträge